Insight Strategy Marketing Ltd.

Other

Moebius Medical Ltd.

Hadasit Medical Research Services and Development Ltd.

Insight Biopharmacenticals Ltd.

Maty Ayal-Hershkovitz

Iris Pecker

Daphna Miron

Israel Vlodavsky

Oron Yacoby-Zeevi

Yinon Shlomi

Yoav Peleg

Hanna Ben-Artzi

Yechezkel Barenholz

Tuvia Peretz

Yael Friedmann

Keren Turjeman

Ayelet Gilboa

Gadi Sarfati

Haim Moskowitz

Yaniv Dolev

Madlene Mimon

Madelene Mimon

Yinon Schlomi

Simha Shemesh

Raphael Mayer

The present invention provides a pharmaceutical composition for the lubrication of joints, the pharmaceutical composition comprising a non-ionic tonicity agent comprising a polyol, and liposomes comprising at least one membrane comprising at least one phospholipid (PL) selected from a glycerophospholipid (GPL), said GPL having two C-Chydrocarbon chains, being the same or different, and sphingomyelin (SM) having a C-Chydrocarbon chain, the pharmaceutical composition being essentially free of an additional pharmaceutically active agent, wherein the at least one membrane has a phase transition temperature in the range of about 20° C. to about 39° C. and the joint has a joint temperature which is above the phase transition temperature.

Liposomal formulation for joint lubrication

The present invention provides a pharmaceutical composition for the lubrication of joints, the pharmaceutical composition comprising a non-ionic tonicity agent comprising a polyol, and liposomes comprising at least one membrane comprising at least one phospholipid (PL) selected from a glycerophospholipid (GPL), said GPL having two C12-C18 hydrocarbon chains, being the same or different, and sphingomyelin (SM) having a C12-C18 hydrocarbon chain, the pharmaceutical composition being essentially free of an additional pharmaceutically active agent, wherein the at least one membrane has a phase transition temperature in the range of about 20&#xb0; C. to about 39&#xb0; C. and the joint has a joint temperature which is above the phase transition temperature.

A method of treating a condition associated with heparanase expression by administering a heparanase activity neutralizing monoclonal anti-heparanase antibody, the monoclonal anti-heparanase antibody being for neutralizing heparanase catalytic activity.

Heparanase activity neutralizing anti-heparanase monoclonal antibody

A method of testing an agent for its potential at modulating induction of a molecular weight change of a first polyion is disclosed. The method is effected by (a) subjecting the first polyion to conditions under-which the first polyion undergoing the molecular weight change in a presence, in an absence or under several different concentrations of the agent; (b) interacting the first polyion with a second polyion having an opposite charge, the second polyion being fluorescently labeled; (c) providing reaction conditions so as to allow molecular weight discriminative interaction between the first polyion and the second polyion; and (d) employing a fluorescence polarization assay for determining a modulating effect of the agent on the induction of the molecular weight change of the first polyion.

High throughput assay for monitoring polycation or polyanion molecular weight, degradation or synthesis

A monoclonal antibody elicited by a heparanase protein or an immunogenical portion thereof, the monoclonal antibody specifically inhibits heparanase activity.

Bacterial, yeast and animal cells and methods for overexpressing recombinant heparanase in cellular systems, methods of purifying recombinant heparanase therefrom and modified heparanase species which serve as precursors for generating highly active heparanase by proteolysis.

Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same

A preparation containing an enzymatically inactive form of heparanase, said enzymatically inactive form of heparanase being cleavable into an enzimatically active form of heparanase.

Qualitative and quantitative methods of testing an agent for its potential at inhibiting glycosidase catalytic activity, the methods including the steps of interacting a glycosidase enzyme with a glycosidase substrate in a presence of the agent and qualitatively or quantitatively evaluating an effect of the agent on the catalytic activity of the glycosidase enzyme toward the glycosidase substrate. Preferably the glycosidase enzyme is a heparanase enzyme and the glycosidase substrate is, respectively, a heparanase substrate.

Growing community of inventors

Herzliya, Israel

Maty Ayal-Hershkovitz